Jean-Pierre Sommadossi

This inventor holds 77 USPTO granted patents and 18 published patent applications and 9 EPO patents, primarily in Viral Infection Treatment (CPC class A61K). Top assignees: Idenix Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc., Universitá Degli Studi Di Cagliari. Active years: 1991-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Pierre Sommadossi. Retrieved from https://idiyas.com/inventor/jean-pierre-sommadossi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 77 (Patent Applications = 18)

% Patents Active = 84.4

EPO Patents = 9 (Patent Applications = 18)

Average Co-Inventor Count = 2.4

ph-index = 27

Forward Citations = 2,476(Granted Patents)

Forward Citations (Not Self Cited) = 1,636(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Vestavia, AL (US) (1992)
Birmingham, AL (US) (1991 - 2013)
Cambridge, MA (US) (2003 - 2016)
Boston, MA (US) (2010 - 2024)

Company Filing History:

30 out of 100

Idenix Pharmaceuticals, Inc.

patents

27 out of 28

Atea Pharmaceuticals, Inc.

patents

16 out of 33

Universitá Degli Studi Di Cagliari

patents

4. 7 out of 5,383

Centre National De La Recherche Scientifique

patents

5. 7 out of 641

The UAB Research Foundation (The University of Alabama at Birmingham)

L'université Montpellier Ii

University of Cagliari

patents

11. 2 out of 871

University of Georgia Research Foundation Inc

L'universite Montpelier Ii

patent

14. 1 out of 329

The University of Alabama

patents

15. 1 out of 298

Universitè De Montpellier

patents

16. 5 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1991-2026

Loading Chart...

Areas of Expertise:

COVID-19

HCV

Purine Nucleotides

Nucleoside Prodrugs

Viral Infections

Epinephrine Malonate

Flaviviruses

Cirrhosis Treatment

Nucleotide Salts

Combination Therapy

Hepatitis C

Resistance Strains

77 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12746251 - NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY (2026-09-29),

2. 12741984 - Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus (2026-09-22),

3. 12551499 - Highly active compounds against COVID-19 (2026-02-17),

4. 12458656 - Advantageous anti-HCV combination therapy (2025-11-04),

5. 12226429 - Highly active compounds against COVID-19 (2025-02-18),

6. 12134588 - Crystalline epinephrine malonate salt (2024-11-05),

7. 12084473 - β-D-2'-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment (2024-09-10),

8. 12006340 - Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus (2024-06-11),

9. 11975016 - 2′-substituted-N-substituted purine nucleotides for RNA virus treatment (2024-05-07),

10. 11813278 - Highly active compounds against COVID-19 (2023-11-14),

11. 11738038 - Highly active compounds against COVID-19 (2023-08-29),

12. 11707480 - Highly active compounds against COVID-19 (2023-07-25),

13. 11690860 - Treatment of HCV infected patients with cirrhosis (2023-07-04),

14. 11505521 - Crystalline epinephrine malonate salt (2022-11-22),

15. 10995059 - Crystalline epinephrine malonate salt (2021-05-04),

Title: The Innovative Journey of Jean-Pierre Sommadossi

Introduction: Jean-Pierre Sommadossi is a visionary inventor based in Boston, MA, known for his groundbreaking contributions to the field of biotechnology and pharmaceuticals.

Latest Patents: Jean-Pierre Sommadossi holds several patents in the areas of drug discovery and development, including novel compounds and therapeutic methods aimed at improving patient outcomes.

Career Highlights: With a distinguished career spanning over two decades, Jean-Pierre Sommadossi has held key roles in leading biotech companies, driving innovation in drug research and development. His expertise lies in translating scientific discoveries into tangible solutions for unmet medical needs.

Collaborations: Throughout his career, Jean-Pierre Sommadossi has collaborated with top researchers, scientists, and industry experts to push the boundaries of biopharmaceutical innovation. His collaborative efforts have led to the development of cutting-edge therapies that have the potential to revolutionize healthcare.

Conclusion: Jean-Pierre Sommadossi's relentless pursuit of innovation and his passion for improving patient care have solidified his reputation as a pioneering inventor in the biotechnology and pharmaceutical sectors. His work continues to inspire the next generation of inventors and researchers in the quest for transformative healthcare solutions.

Profile summary based on public USPTO records.